Artivion announces presentation of Nexus device trial results

Artivion (AORT) announced the presentation of new clinical data from Endospan’s Nexus Triomphe trial at the 105th American Association for Thoracic Surgery Annual Meeting in Seattle. The data presented analyzed clinical outcomes across a 54-patient chronic aortic dissection statistical cohort at 30 days following treatment with Nexus. Patients enrolled were at high risk for open surgical repair. The data demonstrate statistically significant improvement in clinical outcomes and device technical performance compared with the performance goals set forth in the FDA-approved investigational device exemption. 30-day data from Endospan’s trial demonstrate 63% reduction in major adverse event rate compared with reference performance goal. The Nexus Triomphe trial is the US IDE study evaluating the Nexus device in the endovascular treatment of chronic aortic dissection.